Cipla, South Africa’s third-largest pharmaceutical manufacturer, in collaboration with Teva Pharmaceutical Industries Ltd, has announced the launch of the country’s first biosimilar for the oncology and haematology markets.
Filgrastim Teva, manufactured by Teva and distributed in South Africa by Cipla, paves the way for more affordable treatments to aid in the fight against dread diseases such as cancer, according to Paul Miller, CEO of Cipla South Africa.
“This landmark development for the South African pharmaceutical industry only happened after a thorough approval process. Not only does the approval of Filgrastim Teva hold major significance for the advancement of affordable supportive oncology treatments, but the learnings from this process will assist in faster approvals for more biosimilar medicines in future.”
Looking for a affordable Medical Aid or Hospital Plan, just click here Continue reading…